The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...

FDA approves Zepbound for obstructive sleep apnea in obese individuals Discover how this weight-loss drug reduces symptoms ...

Zepbound, a drug approved by the FDA, has been shown to reduce the severity of obstructive sleep apnea in obese adults, ...

Zepbound became the first drug approved by the Food and Drug Administration to treat obstructive sleep apnea in obese adults ...

Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...

The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...

The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but ...

The FDA has declared an end to the shortage of a popular obesity drug. The implications for consumers are complicated.

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) e estimate Rivian’s stock price to be $140.00 per share. Our estimated stock ...

The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...

FDA has approved the first prescription drug, Zepbound, for treating moderate to severe obstructive sleep apnea (OSA) in ...